GE, Affibody to Collaborate on Her2 PET Agent
GE Healthcare signed a deal with Swedish contrast agent developer Affibody AB for the development of a PET imaging agent that targets Human Epidermal Growth Factor Receptor 2 (Her2), a breast cancer biomarker. The companies expect that the product will begin clinical trials by year’s end as to its effectiveness in helping to determine the presence or recurrence of certain types of breast cancers.